The global Recombinant Protein Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Recombinant Protein Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Protein Drugs.

Report Scope

The Recombinant Protein Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Protein Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Recombinant Protein Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Recombinant Protein Drugs Market Report

Report Metric	Details
Report Name	Recombinant Protein Drugs Market
CAGR	5%
Segment by Type	rhIFN rhEPO rhG-CSF Recombinant insulin Others
Segment by Application	Pharmaceutical Industry Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Novo Nordisk, Amgen, Sanofi, Eli Lilly, Merck Serono, Ortho Biotech, Roche, Kyowa Hakko Kirin, Pharmingen, Abcam, GenSci, SL PHARM, Dongbao Pharm, Ankebio, NCPC, Heng Rui
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Protein Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Protein Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Recombinant Protein Drugs Market report?

Ans: The main players in the Recombinant Protein Drugs Market are Novo Nordisk, Amgen, Sanofi, Eli Lilly, Merck Serono, Ortho Biotech, Roche, Kyowa Hakko Kirin, Pharmingen, Abcam, GenSci, SL PHARM, Dongbao Pharm, Ankebio, NCPC, Heng Rui

What are the Application segmentation covered in the Recombinant Protein Drugs Market report?

Ans: The Applications covered in the Recombinant Protein Drugs Market report are Pharmaceutical Industry, Others

What are the Type segmentation covered in the Recombinant Protein Drugs Market report?

Ans: The Types covered in the Recombinant Protein Drugs Market report are rhIFN, rhEPO, rhG-CSF, Recombinant insulin, Others

1 Recombinant Protein Drugs Market Overview

1.1 Product Overview and Scope of Recombinant Protein Drugs

1.2 Recombinant Protein Drugs Segment by Type

1.2.1 Global Recombinant Protein Drugs Market Value Comparison by Type (2024-2030)

1.2.2 rhIFN

1.2.3 rhEPO

1.2.4 rhG-CSF

1.2.5 Recombinant insulin

1.2.6 Others

1.3 Recombinant Protein Drugs Segment by Application

1.3.1 Global Recombinant Protein Drugs Market Value by Application: (2024-2030)

1.3.2 Pharmaceutical Industry

1.3.3 Others

1.4 Global Recombinant Protein Drugs Market Size Estimates and Forecasts

1.4.1 Global Recombinant Protein Drugs Revenue 2019-2030

1.4.2 Global Recombinant Protein Drugs Sales 2019-2030

1.4.3 Global Recombinant Protein Drugs Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Recombinant Protein Drugs Market Competition by Manufacturers

2.1 Global Recombinant Protein Drugs Sales Market Share by Manufacturers (2019-2024)

2.2 Global Recombinant Protein Drugs Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Recombinant Protein Drugs Average Price by Manufacturers (2019-2024)

2.4 Global Recombinant Protein Drugs Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Recombinant Protein Drugs, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Recombinant Protein Drugs, Product Type & Application

2.7 Recombinant Protein Drugs Market Competitive Situation and Trends

2.7.1 Recombinant Protein Drugs Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Recombinant Protein Drugs Players Market Share by Revenue

2.7.3 Global Recombinant Protein Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Recombinant Protein Drugs Retrospective Market Scenario by Region

3.1 Global Recombinant Protein Drugs Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Recombinant Protein Drugs Global Recombinant Protein Drugs Sales by Region: 2019-2030

3.2.1 Global Recombinant Protein Drugs Sales by Region: 2019-2024

3.2.2 Global Recombinant Protein Drugs Sales by Region: 2025-2030

3.3 Global Recombinant Protein Drugs Global Recombinant Protein Drugs Revenue by Region: 2019-2030

3.3.1 Global Recombinant Protein Drugs Revenue by Region: 2019-2024

3.3.2 Global Recombinant Protein Drugs Revenue by Region: 2025-2030

3.4 North America Recombinant Protein Drugs Market Facts & Figures by Country

3.4.1 North America Recombinant Protein Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Recombinant Protein Drugs Sales by Country (2019-2030)

3.4.3 North America Recombinant Protein Drugs Revenue by Country (2019-2030)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Recombinant Protein Drugs Market Facts & Figures by Country

3.5.1 Europe Recombinant Protein Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Recombinant Protein Drugs Sales by Country (2019-2030)

3.5.3 Europe Recombinant Protein Drugs Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Recombinant Protein Drugs Market Facts & Figures by Country

3.6.1 Asia Pacific Recombinant Protein Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Recombinant Protein Drugs Sales by Country (2019-2030)

3.6.3 Asia Pacific Recombinant Protein Drugs Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Recombinant Protein Drugs Market Facts & Figures by Country

3.7.1 Latin America Recombinant Protein Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Recombinant Protein Drugs Sales by Country (2019-2030)

3.7.3 Latin America Recombinant Protein Drugs Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Recombinant Protein Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa Recombinant Protein Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Recombinant Protein Drugs Sales by Country (2019-2030)

3.8.3 Middle East and Africa Recombinant Protein Drugs Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Recombinant Protein Drugs Sales by Type (2019-2030)

4.1.1 Global Recombinant Protein Drugs Sales by Type (2019-2024)

4.1.2 Global Recombinant Protein Drugs Sales by Type (2025-2030)

4.1.3 Global Recombinant Protein Drugs Sales Market Share by Type (2019-2030)

4.2 Global Recombinant Protein Drugs Revenue by Type (2019-2030)

4.2.1 Global Recombinant Protein Drugs Revenue by Type (2019-2024)

4.2.2 Global Recombinant Protein Drugs Revenue by Type (2025-2030)

4.2.3 Global Recombinant Protein Drugs Revenue Market Share by Type (2019-2030)

4.3 Global Recombinant Protein Drugs Price by Type (2019-2030)

5 Segment by Application

5.1 Global Recombinant Protein Drugs Sales by Application (2019-2030)

5.1.1 Global Recombinant Protein Drugs Sales by Application (2019-2024)

5.1.2 Global Recombinant Protein Drugs Sales by Application (2025-2030)

5.1.3 Global Recombinant Protein Drugs Sales Market Share by Application (2019-2030)

5.2 Global Recombinant Protein Drugs Revenue by Application (2019-2030)

5.2.1 Global Recombinant Protein Drugs Revenue by Application (2019-2024)

5.2.2 Global Recombinant Protein Drugs Revenue by Application (2025-2030)

5.2.3 Global Recombinant Protein Drugs Revenue Market Share by Application (2019-2030)

5.3 Global Recombinant Protein Drugs Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Novo Nordisk

6.1.1 Novo Nordisk Corporation Information

6.1.2 Novo Nordisk Description and Business Overview

6.1.3 Novo Nordisk Recombinant Protein Drugs Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Novo Nordisk Recombinant Protein Drugs Product Portfolio

6.1.5 Novo Nordisk Recent Developments/Updates

6.2 Amgen

6.2.1 Amgen Corporation Information

6.2.2 Amgen Description and Business Overview

6.2.3 Amgen Recombinant Protein Drugs Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Amgen Recombinant Protein Drugs Product Portfolio

6.2.5 Amgen Recent Developments/Updates

6.3 Sanofi

6.3.1 Sanofi Corporation Information

6.3.2 Sanofi Description and Business Overview

6.3.3 Sanofi Recombinant Protein Drugs Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Sanofi Recombinant Protein Drugs Product Portfolio

6.3.5 Sanofi Recent Developments/Updates

6.4 Eli Lilly

6.4.1 Eli Lilly Corporation Information

6.4.2 Eli Lilly Description and Business Overview

6.4.3 Eli Lilly Recombinant Protein Drugs Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Eli Lilly Recombinant Protein Drugs Product Portfolio

6.4.5 Eli Lilly Recent Developments/Updates

6.5 Merck Serono

6.5.1 Merck Serono Corporation Information

6.5.2 Merck Serono Description and Business Overview

6.5.3 Merck Serono Recombinant Protein Drugs Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Merck Serono Recombinant Protein Drugs Product Portfolio

6.5.5 Merck Serono Recent Developments/Updates

6.6 Ortho Biotech

6.6.1 Ortho Biotech Corporation Information

6.6.2 Ortho Biotech Description and Business Overview

6.6.3 Ortho Biotech Recombinant Protein Drugs Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Ortho Biotech Recombinant Protein Drugs Product Portfolio

6.6.5 Ortho Biotech Recent Developments/Updates

6.7 Roche

6.6.1 Roche Corporation Information

6.6.2 Roche Description and Business Overview

6.6.3 Roche Recombinant Protein Drugs Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Roche Recombinant Protein Drugs Product Portfolio

6.7.5 Roche Recent Developments/Updates

6.8 Kyowa Hakko Kirin

6.8.1 Kyowa Hakko Kirin Corporation Information

6.8.2 Kyowa Hakko Kirin Description and Business Overview

6.8.3 Kyowa Hakko Kirin Recombinant Protein Drugs Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Kyowa Hakko Kirin Recombinant Protein Drugs Product Portfolio

6.8.5 Kyowa Hakko Kirin Recent Developments/Updates

6.9 Pharmingen

6.9.1 Pharmingen Corporation Information

6.9.2 Pharmingen Description and Business Overview

6.9.3 Pharmingen Recombinant Protein Drugs Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Pharmingen Recombinant Protein Drugs Product Portfolio

6.9.5 Pharmingen Recent Developments/Updates

6.10 Abcam

6.10.1 Abcam Corporation Information

6.10.2 Abcam Description and Business Overview

6.10.3 Abcam Recombinant Protein Drugs Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Abcam Recombinant Protein Drugs Product Portfolio

6.10.5 Abcam Recent Developments/Updates

6.11 GenSci

6.11.1 GenSci Corporation Information

6.11.2 GenSci Recombinant Protein Drugs Description and Business Overview

6.11.3 GenSci Recombinant Protein Drugs Sales, Revenue and Gross Margin (2019-2024)

6.11.4 GenSci Recombinant Protein Drugs Product Portfolio

6.11.5 GenSci Recent Developments/Updates

6.12 SL PHARM

6.12.1 SL PHARM Corporation Information

6.12.2 SL PHARM Recombinant Protein Drugs Description and Business Overview

6.12.3 SL PHARM Recombinant Protein Drugs Sales, Revenue and Gross Margin (2019-2024)

6.12.4 SL PHARM Recombinant Protein Drugs Product Portfolio

6.12.5 SL PHARM Recent Developments/Updates

6.13 Dongbao Pharm

6.13.1 Dongbao Pharm Corporation Information

6.13.2 Dongbao Pharm Recombinant Protein Drugs Description and Business Overview

6.13.3 Dongbao Pharm Recombinant Protein Drugs Sales, Revenue and Gross Margin (2019-2024)

6.13.4 Dongbao Pharm Recombinant Protein Drugs Product Portfolio

6.13.5 Dongbao Pharm Recent Developments/Updates

6.14 Ankebio

6.14.1 Ankebio Corporation Information

6.14.2 Ankebio Recombinant Protein Drugs Description and Business Overview

6.14.3 Ankebio Recombinant Protein Drugs Sales, Revenue and Gross Margin (2019-2024)

6.14.4 Ankebio Recombinant Protein Drugs Product Portfolio

6.14.5 Ankebio Recent Developments/Updates

6.15 NCPC

6.15.1 NCPC Corporation Information

6.15.2 NCPC Recombinant Protein Drugs Description and Business Overview

6.15.3 NCPC Recombinant Protein Drugs Sales, Revenue and Gross Margin (2019-2024)

6.15.4 NCPC Recombinant Protein Drugs Product Portfolio

6.15.5 NCPC Recent Developments/Updates

6.16 Heng Rui

6.16.1 Heng Rui Corporation Information

6.16.2 Heng Rui Recombinant Protein Drugs Description and Business Overview

6.16.3 Heng Rui Recombinant Protein Drugs Sales, Revenue and Gross Margin (2019-2024)

6.16.4 Heng Rui Recombinant Protein Drugs Product Portfolio

6.16.5 Heng Rui Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Recombinant Protein Drugs Industry Chain Analysis

7.2 Recombinant Protein Drugs Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Recombinant Protein Drugs Production Mode & Process

7.4 Recombinant Protein Drugs Sales and Marketing

7.4.1 Recombinant Protein Drugs Sales Channels

7.4.2 Recombinant Protein Drugs Distributors

7.5 Recombinant Protein Drugs Customers

8 Recombinant Protein Drugs Market Dynamics

8.1 Recombinant Protein Drugs Industry Trends

8.2 Recombinant Protein Drugs Market Drivers

8.3 Recombinant Protein Drugs Market Challenges

8.4 Recombinant Protein Drugs Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Recombinant Protein Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Recombinant Protein Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Recombinant Protein Drugs Market Competitive Situation by Manufacturers in 2023

Table 4. Global Recombinant Protein Drugs Sales (K Doses) of Key Manufacturers (2019-2024)

Table 5. Global Recombinant Protein Drugs Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Recombinant Protein Drugs Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Recombinant Protein Drugs Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Recombinant Protein Drugs Average Price (USD/Dose) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Recombinant Protein Drugs, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Recombinant Protein Drugs, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Recombinant Protein Drugs, Product Type & Application

Table 12. Global Key Manufacturers of Recombinant Protein Drugs, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Recombinant Protein Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Protein Drugs as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Recombinant Protein Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Recombinant Protein Drugs Sales by Region (2019-2024) & (K Doses)

Table 18. Global Recombinant Protein Drugs Sales Market Share by Region (2019-2024)

Table 19. Global Recombinant Protein Drugs Sales by Region (2025-2030) & (K Doses)

Table 20. Global Recombinant Protein Drugs Sales Market Share by Region (2025-2030)

Table 21. Global Recombinant Protein Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Recombinant Protein Drugs Revenue Market Share by Region (2019-2024)

Table 23. Global Recombinant Protein Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Recombinant Protein Drugs Revenue Market Share by Region (2025-2030)

Table 25. North America Recombinant Protein Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Recombinant Protein Drugs Sales by Country (2019-2024) & (K Doses)

Table 27. North America Recombinant Protein Drugs Sales by Country (2025-2030) & (K Doses)

Table 28. North America Recombinant Protein Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Recombinant Protein Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Recombinant Protein Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Recombinant Protein Drugs Sales by Country (2019-2024) & (K Doses)

Table 32. Europe Recombinant Protein Drugs Sales by Country (2025-2030) & (K Doses)

Table 33. Europe Recombinant Protein Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Recombinant Protein Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Recombinant Protein Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Recombinant Protein Drugs Sales by Region (2019-2024) & (K Doses)

Table 37. Asia Pacific Recombinant Protein Drugs Sales by Region (2025-2030) & (K Doses)

Table 38. Asia Pacific Recombinant Protein Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Recombinant Protein Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Recombinant Protein Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Recombinant Protein Drugs Sales by Country (2019-2024) & (K Doses)

Table 42. Latin America Recombinant Protein Drugs Sales by Country (2025-2030) & (K Doses)

Table 43. Latin America Recombinant Protein Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Recombinant Protein Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Recombinant Protein Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Recombinant Protein Drugs Sales by Country (2019-2024) & (K Doses)

Table 47. Middle East & Africa Recombinant Protein Drugs Sales by Country (2025-2030) & (K Doses)

Table 48. Middle East & Africa Recombinant Protein Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Recombinant Protein Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Recombinant Protein Drugs Sales (K Doses) by Type (2019-2024)

Table 51. Global Recombinant Protein Drugs Sales (K Doses) by Type (2025-2030)

Table 52. Global Recombinant Protein Drugs Sales Market Share by Type (2019-2024)

Table 53. Global Recombinant Protein Drugs Sales Market Share by Type (2025-2030)

Table 54. Global Recombinant Protein Drugs Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Recombinant Protein Drugs Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Recombinant Protein Drugs Revenue Market Share by Type (2019-2024)

Table 57. Global Recombinant Protein Drugs Revenue Market Share by Type (2025-2030)

Table 58. Global Recombinant Protein Drugs Price (USD/Dose) by Type (2019-2024)

Table 59. Global Recombinant Protein Drugs Price (USD/Dose) by Type (2025-2030)

Table 60. Global Recombinant Protein Drugs Sales (K Doses) by Application (2019-2024)

Table 61. Global Recombinant Protein Drugs Sales (K Doses) by Application (2025-2030)

Table 62. Global Recombinant Protein Drugs Sales Market Share by Application (2019-2024)

Table 63. Global Recombinant Protein Drugs Sales Market Share by Application (2025-2030)

Table 64. Global Recombinant Protein Drugs Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Recombinant Protein Drugs Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Recombinant Protein Drugs Revenue Market Share by Application (2019-2024)

Table 67. Global Recombinant Protein Drugs Revenue Market Share by Application (2025-2030)

Table 68. Global Recombinant Protein Drugs Price (USD/Dose) by Application (2019-2024)

Table 69. Global Recombinant Protein Drugs Price (USD/Dose) by Application (2025-2030)

Table 70. Novo Nordisk Corporation Information

Table 71. Novo Nordisk Description and Business Overview

Table 72. Novo Nordisk Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 73. Novo Nordisk Recombinant Protein Drugs Product

Table 74. Novo Nordisk Recent Developments/Updates

Table 75. Amgen Corporation Information

Table 76. Amgen Description and Business Overview

Table 77. Amgen Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 78. Amgen Recombinant Protein Drugs Product

Table 79. Amgen Recent Developments/Updates

Table 80. Sanofi Corporation Information

Table 81. Sanofi Description and Business Overview

Table 82. Sanofi Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 83. Sanofi Recombinant Protein Drugs Product

Table 84. Sanofi Recent Developments/Updates

Table 85. Eli Lilly Corporation Information

Table 86. Eli Lilly Description and Business Overview

Table 87. Eli Lilly Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 88. Eli Lilly Recombinant Protein Drugs Product

Table 89. Eli Lilly Recent Developments/Updates

Table 90. Merck Serono Corporation Information

Table 91. Merck Serono Description and Business Overview

Table 92. Merck Serono Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 93. Merck Serono Recombinant Protein Drugs Product

Table 94. Merck Serono Recent Developments/Updates

Table 95. Ortho Biotech Corporation Information

Table 96. Ortho Biotech Description and Business Overview

Table 97. Ortho Biotech Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 98. Ortho Biotech Recombinant Protein Drugs Product

Table 99. Ortho Biotech Recent Developments/Updates

Table 100. Roche Corporation Information

Table 101. Roche Description and Business Overview

Table 102. Roche Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 103. Roche Recombinant Protein Drugs Product

Table 104. Roche Recent Developments/Updates

Table 105. Kyowa Hakko Kirin Corporation Information

Table 106. Kyowa Hakko Kirin Description and Business Overview

Table 107. Kyowa Hakko Kirin Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 108. Kyowa Hakko Kirin Recombinant Protein Drugs Product

Table 109. Kyowa Hakko Kirin Recent Developments/Updates

Table 110. Pharmingen Corporation Information

Table 111. Pharmingen Description and Business Overview

Table 112. Pharmingen Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 113. Pharmingen Recombinant Protein Drugs Product

Table 114. Pharmingen Recent Developments/Updates

Table 115. Abcam Corporation Information

Table 116. Abcam Description and Business Overview

Table 117. Abcam Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 118. Abcam Recombinant Protein Drugs Product

Table 119. Abcam Recent Developments/Updates

Table 120. GenSci Corporation Information

Table 121. GenSci Description and Business Overview

Table 122. GenSci Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 123. GenSci Recombinant Protein Drugs Product

Table 124. GenSci Recent Developments/Updates

Table 125. SL PHARM Corporation Information

Table 126. SL PHARM Description and Business Overview

Table 127. SL PHARM Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 128. SL PHARM Recombinant Protein Drugs Product

Table 129. SL PHARM Recent Developments/Updates

Table 130. Dongbao Pharm Corporation Information

Table 131. Dongbao Pharm Description and Business Overview

Table 132. Dongbao Pharm Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 133. Dongbao Pharm Recombinant Protein Drugs Product

Table 134. Dongbao Pharm Recent Developments/Updates

Table 135. Ankebio Corporation Information

Table 136. Ankebio Description and Business Overview

Table 137. Ankebio Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 138. Ankebio Recombinant Protein Drugs Product

Table 139. Ankebio Recent Developments/Updates

Table 140. NCPC Corporation Information

Table 141. NCPC Description and Business Overview

Table 142. NCPC Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 143. NCPC Recombinant Protein Drugs Product

Table 144. NCPC Recent Developments/Updates

Table 145. Heng Rui Corporation Information

Table 146. Heng Rui Description and Business Overview

Table 147. Heng Rui Recombinant Protein Drugs Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 148. Heng Rui Recombinant Protein Drugs Product

Table 149. Heng Rui Recent Developments/Updates

Table 150. Key Raw Materials Lists

Table 151. Raw Materials Key Suppliers Lists

Table 152. Recombinant Protein Drugs Distributors List

Table 153. Recombinant Protein Drugs Customers List

Table 154. Recombinant Protein Drugs Market Trends

Table 155. Recombinant Protein Drugs Market Drivers

Table 156. Recombinant Protein Drugs Market Challenges

Table 157. Recombinant Protein Drugs Market Restraints

Table 158. Research Programs/Design for This Report

Table 159. Key Data Information from Secondary Sources

Table 160. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Recombinant Protein Drugs

Figure 2. Global Recombinant Protein Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Recombinant Protein Drugs Market Share by Type in 2023 & 2030

Figure 4. rhIFN Product Picture

Figure 5. rhEPO Product Picture

Figure 6. rhG-CSF Product Picture

Figure 7. Recombinant insulin Product Picture

Figure 8. Others Product Picture

Figure 9. Global Recombinant Protein Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 10. Global Recombinant Protein Drugs Market Share by Application in 2023 & 2030

Figure 11. Pharmaceutical Industry

Figure 12. Others

Figure 13. Global Recombinant Protein Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Recombinant Protein Drugs Market Size (2019-2030) & (US$ Million)

Figure 15. Global Recombinant Protein Drugs Sales (2019-2030) & (K Doses)

Figure 16. Global Recombinant Protein Drugs Average Price (USD/Dose) & (2019-2030)

Figure 17. Recombinant Protein Drugs Report Years Considered

Figure 18. Recombinant Protein Drugs Sales Share by Manufacturers in 2023

Figure 19. Global Recombinant Protein Drugs Revenue Share by Manufacturers in 2023

Figure 20. The Global 5 and 10 Largest Recombinant Protein Drugs Players: Market Share by Revenue in 2023

Figure 21. Recombinant Protein Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 22. Global Recombinant Protein Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 23. North America Recombinant Protein Drugs Sales Market Share by Country (2019-2030)

Figure 24. North America Recombinant Protein Drugs Revenue Market Share by Country (2019-2030)

Figure 25. U.S. Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Canada Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 27. Europe Recombinant Protein Drugs Sales Market Share by Country (2019-2030)

Figure 28. Europe Recombinant Protein Drugs Revenue Market Share by Country (2019-2030)

Figure 29. Germany Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. France Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. U.K. Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Italy Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Russia Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Asia Pacific Recombinant Protein Drugs Sales Market Share by Region (2019-2030)

Figure 35. Asia Pacific Recombinant Protein Drugs Revenue Market Share by Region (2019-2030)

Figure 36. China Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. Japan Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. South Korea Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. India Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Australia Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Taiwan Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Indonesia Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Thailand Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Malaysia Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Philippines Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Latin America Recombinant Protein Drugs Sales Market Share by Country (2019-2030)

Figure 47. Latin America Recombinant Protein Drugs Revenue Market Share by Country (2019-2030)

Figure 48. Mexico Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Brazil Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Argentina Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. Middle East & Africa Recombinant Protein Drugs Sales Market Share by Country (2019-2030)

Figure 52. Middle East & Africa Recombinant Protein Drugs Revenue Market Share by Country (2019-2030)

Figure 53. Turkey Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 54. Saudi Arabia Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 55. U.A.E Recombinant Protein Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 56. Global Sales Market Share of Recombinant Protein Drugs by Type (2019-2030)

Figure 57. Global Revenue Market Share of Recombinant Protein Drugs by Type (2019-2030)

Figure 58. Global Recombinant Protein Drugs Price (USD/Dose) by Type (2019-2030)

Figure 59. Global Sales Market Share of Recombinant Protein Drugs by Application (2019-2030)

Figure 60. Global Revenue Market Share of Recombinant Protein Drugs by Application (2019-2030)

Figure 61. Global Recombinant Protein Drugs Price (USD/Dose) by Application (2019-2030)

Figure 62. Recombinant Protein Drugs Value Chain

Figure 63. Recombinant Protein Drugs Production Process

Figure 64. Channels of Distribution (Direct Vs Distribution)

Figure 65. Distributors Profiles

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions